No Data
Spot information for individual stocks (1)
Sumitomo Pharma <4506.T> hits the upper limit. The core operating profit Financial Estimates (consolidated) for the fiscal year ending March 2025 have been raised. Sales of the advanced prostate cancer treatment "Orgovyx" have increased. Komatsu Wall <7949.T> hits the upper limit in buy orders. The consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is 4.1 billion yen (a 12% increase compared to the previous period). The level of Dividends will be raised from 3.0% as the lower limit of DOEs (Return on Equity) to a target of 6%. SMS <2175.T> has risen for nine consecutive days. The consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is...
The Nikkei average rose by 205 yen, extending its gains for five consecutive days, recovering to 36,000 yen at the close for the first time in a month = 30th afternoon session.
On the 30th, the Nikkei average stock price in the afternoon session increased by 205.39 yen to 36,045.38 yen, marking a five-day rise. The TOPIX (Tokyo Stock Price Index) also rose by 16.68 points to 2,667.29 points. The Nikkei average surpassed the psychological barrier of 36,000 yen for the first time in a month since March 28 (37,120.33 yen) on a closing basis. While buying tended to lead in the morning, there were also moments when selling in anticipation of a pullback led to heavier trading. However, as the afternoon session began, the exchange rate temporarily.
Stocks that moved and those that were traded in the front market.
* Komatsu Wall <7949> 1780 - The significant increase in the dividend plan raises the appeal of the yield. * Sumitomo Pharma <4506> 787 +100 The substantial upward revision beyond expectations has an impact. * Square Enix HD <9684> 8121 +993 3D Investment emerged as a major shareholder. * S.M.S <2175> 1360 +168 The forecast of double-digit profit growth this period and the strengthening of shareholder returns are well received. * Genky Drug Stores <9267> 3630 +42
Genki Dora surged to an all-time high since the beginning of the year, with the FY2025 third quarter results landing on increased revenue and profit.
Genky DrugStores (ゲンキードラ) <9267.T> surged sharply. At one point, it rose by 470 yen to 3,675 yen, significantly updating the year-to-date high of 3,460 yen on the 24th. After the market closed on the 28th, the consolidated financial results for the third quarter of the fiscal year ending June 2025 (June 21, 2024 - March 20, 2025) were announced. The results showed an increase in both revenue and operating profit, which was well received. The third quarter financial results showed revenue of 147.83 billion yen (a 7.9% increase compared to the same period last year) and operating profit of 6.839 billion yen (a 5.3% increase compared to the same period last year). Concentration.
The Nikkei average is up about 50 yen, and after buying, it shows heavy movement at the upper levels = 30 days before the morning session.
On the 30th at 10:08 AM, the Nikkei average stock price fluctuated around 35,890 yen, down about 50 yen compared to the previous trading day. At 9:09 AM, it reached 36,023 yen 24 sen, up 183 yen 25 sen. In the U.S. market on the 29th, the announcement by the U.S. government to reduce tariffs on imported components for completed vehicles produced domestically was well received, leading to the Dow Inc rising for the sixth consecutive day and a rebound in the Nasdaq Composite Index. Japanese stocks also saw buying ahead of the rise in U.S. stocks. However, after the initial buying settled down.
Key points of attention for the PTS on the 28th = SMS, Kikkoman, Sekisui House.
▽ SMS <2175.T>, Earnings Reports and Stock Buyback ▽ Kikkoman <2801.T>, Earnings Reports and Increased Dividends and Stock Buyback ▽ Sekisui Chemical <4204.T>, Earnings Reports and Revision of Financial Estimates and Stock Buyback ▽ Autech <1736.T>, Revision of Performance and Financial Estimates ▽ Kudo Construction <1764.T>, Acquisition of Stocks of Matsushita Industrial (Subsidiarization) ▽ Marudai Food <2288.T>, Revision of Performance Estimates and Special Loss Recording ▽ Core <2359.T>, Earnings Reports and Review of Medium-term Management Plan Objectives
